Dynamic biomarkers in hormone receptor-positive/HER2-negative breast cancer trials: a new hope for precision oncologyG Grazia, F. Schettini, Javier Cortés et al.|npj Breast Cancer|2026Cited by 6
Data from Palbociclib, Trastuzumab, and Endocrine Therapy in Pretreated HER2-Positive and PAM50 Luminal Advanced Breast Cancer: Randomized Phase II, SOLTI-1303 PATRICIA TrialEva Ciruelos, A. Prat, Tomás Pascual et al.|Unknown|2026Cited by 0
Supplementary Data 1 from Palbociclib, Trastuzumab, and Endocrine Therapy in Pretreated HER2-Positive and PAM50 Luminal Advanced Breast Cancer: Randomized Phase II, SOLTI-1303 PATRICIA TrialEva Ciruelos, A. Prat, Tomás Pascual et al.|Unknown|2026Cited by 0
Real-world second- and third-line progression-free survival after progression on first-line CDK4/6 inhibitors in HR+/HER2- metastatic breast cancer by PAM50 intrinsic subtype: the SOLTI-1801 CDK-PREDICT studyPablo Tolosa, Eva Ciruelos, Isabel García-Fructuoso et al.|Breast Cancer Research and Treatment|2026Cited by 0